Join­ing No­var­tis in siR­NA space, As­traZeneca hands Si­lence $80M up­front for dis­cov­ery deal

Mene Pan­ga­los is dou­bling down on RNA-based tech­nolo­gies for his side of the As­traZeneca R&D ma­chine.

Just two months af­ter bring­ing a small ac­ti­vat­ing RNA …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.